We are live on ! Find out more
ANIX icon

Anixa Biosciences
ANIX

16 hedge funds and large institutions have $4.36M invested in Anixa Biosciences in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% more ownership

Funds ownership: 6.5% → 6.57% (+0.08%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

6% less funds holding

Funds holding: 17 → 16 (-1)

17% less capital invested

Capital invested by funds: $5.25M → $4.36M (-$895K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$110K
2
SFS
Strategic Financial Services
New York
+$92.6K
3
TRCT
Tower Research Capital (TRC)
New York
+$19.1K
4
Morgan Stanley
Morgan Stanley
New York
+$16.4K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$4.42K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$129K
2
BlackRock
BlackRock
New York
-$17.9K
3
Bank of America
Bank of America
North Carolina
-$16.3K
4
Victory Capital Management
Victory Capital Management
Texas
-$14K
5
Northern Trust
Northern Trust
Illinois
-$8.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.19M +$561 +153 +0%
UBS Group
2
UBS Group
Switzerland
$955K +$110K +30,017 +11%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$336K – – –
BlackRock
4
BlackRock
New York
$266K -$17.9K -4,891 -6%
Northern Trust
5
Northern Trust
Illinois
$176K -$8.7K -2,371 -4%
Bank of New York Mellon
6
Bank of New York Mellon
New York
$134K +$4.42K +1,204 +3%
SFS
7
Strategic Financial Services
New York
$83K +$92.6K +25,250 New
Morgan Stanley
8
Morgan Stanley
New York
$58K +$16.4K +4,470 +34%
SBH
9
Segall Bryant & Hamill
Illinois
$57K – – –
RJA
10
Raymond James & Associates
Florida
$33K – – –
Wells Fargo
11
Wells Fargo
California
$26K -$367 -100 -1%
TRCT
12
Tower Research Capital (TRC)
New York
$20K +$19.1K +5,210 +574%
Bank of America
13
Bank of America
North Carolina
$13K -$16.3K -4,432 -53%
JP Morgan Chase
14
JP Morgan Chase
New York
$5K -$129K -35,170 -96%
Victory Capital Management
15
Victory Capital Management
Texas
– -$14K -3,534 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$1K -369 Closed
Barclays
17
Barclays
United Kingdom
– +$4 +1 New

ANIX Hedge Fund Activity: Q4 2019 in Review

16 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2019, worth a combined $4.36M — down 17% from $5.25M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ANIX and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.

The largest buyer was UBS Group, adding an estimated $110K. The largest seller was JP Morgan Chase, cutting an estimated $129K.

  • 16 institutional investors held Anixa Biosciences (ANIX) as of Q4 2019, down from 17 in Q3 2019.
  • Funds reported $4.36M of Anixa Biosciences stock for Q4 2019, down 17% quarter-over-quarter.
  • 2 funds opened new Anixa Biosciences positions in Q4 2019 and 3 closed out, a net change of -1 holder.
  • The largest Anixa Biosciences buyer in Q4 2019 was UBS Group, an estimated $110K added.
  • The largest Anixa Biosciences seller in Q4 2019 was JP Morgan Chase, an estimated $129K sold.

Based on aggregated 13F filings for Q4 2019.